|
Daily Medical Update
Psoriasis & Psoriatic Arthritis (Biologics in primary care)
Saturday, March 14, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Lancet Rheumatology (2026) - Multicenter Randomized Controlled Trial
Key Findings
- A biologic-first treat-to-target pathway produced better 1-year disease control versus standard step-up care in early PsA.
- The between-strategy difference favored earlier escalation, with higher rates of low-disease-activity targets versus delayed biologic sequencing.
📋 Practice Implication: When inflammatory arthritis is suspected in a patient with psoriasis, prioritize rapid rheumatology referral rather than serial prolonged trial-and-error escalation in primary care.
|
Lancet Rheumatology (2025) - Randomized Controlled Trial
Key Findings
- Golimumab-containing induction achieved greater early clinical response versus methotrexate-focused therapy in treatment-naive PsA.
- Response separation emerged within the randomized treatment window, indicating superior early suppression of active inflammatory disease.
📋 Practice Implication: For newly diagnosed PsA phenotypes with substantial joint burden, document objective inflammatory features early to support timely biologic-eligible specialist pathways.
|
Annals of the Rheumatic Diseases (2025) - Randomized Controlled Trial
Key Findings
- Selective IL-23 inhibition lowered radiographic structural progression versus placebo by week 24 in active PsA.
- Benefits extended beyond symptom scores, with reduced objective progression risk relative to comparator care.
📋 Practice Implication: Use follow-up visits to reinforce adherence and rapid re-assessment for persistent inflammation, because uncontrolled PsA can progress structurally even when pain fluctuates.
|
Lancet (2025) - Phase 3 Randomized Controlled Trial
Key Findings
- Icotrokinra improved key psoriasis efficacy endpoints versus placebo and showed stronger response metrics versus active comparator deucravacitinib.
- Randomized phase 3 results showed higher skin-clearance response versus placebo with acceptable short-term tolerability across study arms.
📋 Practice Implication: In patients declining injectables, discuss that high-efficacy oral targeted options are expanding and may justify expedited dermatology referral instead of cycling lower-yield systemic choices.
|
NEJM (2025) - Randomized Controlled Trial
Key Findings
- Randomized treatment produced significantly greater skin-clearance outcomes versus placebo in moderate-to-severe plaque psoriasis.
- Benefit improved versus placebo across age strata, supporting efficacy signals in both adult and adolescent populations.
📋 Practice Implication: For adolescent and family counseling in primary care, set expectations that specialist pathways now include oral targeted therapies with trial-level efficacy, not only injectable biologics.
|
NEJM Evidence (2025) - Randomized Controlled Trial
Key Findings
- Compared with placebo, icotrokinra improved outcomes in high-impact sites including scalp and nail involvement.
- Site-specific response supports meaningful improvement where quality-of-life burden is disproportionately high.
📋 Practice Implication: Add routine scalp/nail/genital symptom screening in psoriasis visits, since high-impact-site disease can justify earlier systemic-treatment discussions even when total BSA seems modest.
|
Frontiers in Immunology (2025) - Systematic Review/Network Meta-analysis
Key Findings
- Across randomized evidence, IL-17 and IL-23 pathway inhibitors consistently ranked among top options for multiple PsA efficacy domains.
- Comparative results showed class-level differences in endpoint performance, indicating that not all biologics deliver equivalent domain-specific benefit.
📋 Practice Implication: Coordinate referrals with phenotype detail (enthesitis, dactylitis, skin severity, bowel history) so specialists can match biologic class to dominant disease domains from the outset.
|
JDDG (2026) - Practice Guideline
Key Findings
- Guideline recommendations support stratified systemic treatment with biologics as standard options for moderate-to-severe psoriasis.
- Monitoring guidance emphasizes risk-based screening and improved treatment-target tracking during long-term therapy.
📋 Practice Implication: Standardize a pre-biologic primary-care checklist (vaccination status, latent infection risk, cardiometabolic profile, mental health burden) to reduce specialist-start delays and improve safety readiness.
|
|
Recent psoriasis/PsA evidence reinforces earlier use of high-efficacy targeted therapies and tighter phenotype-based treatment selection. New randomized and network evidence suggests stronger short-term skin and joint outcomes with modern IL-23/IL-17 and emerging oral targeted agents, while strategy trials in early PsA support avoiding prolonged step-up delay. For primary care, the highest-value change is faster referral, structured baseline safety screening, and comorbidity-informed coordination before and during biologic care.
|
|